1.
Dunbar L., Wunderink R., Habib M., et al. High-dose, shortcourse levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37:752-60.
2.
Karlowsky J., Thornsberry C., Critchley I., et al. Susceptibilities to levofloxacin in Streptococcus pneumo3 niae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: Results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob Аgents Сhemother 2003; 47:1790–7.
3.
Jonas D., Engels I., Friedhoff C., Spitzmuller B., Daschner F., Frank U. Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila. J Antimicrob Chemother 2001; 47:147-52.
4.
Critchley I., Jones M., Heinze P., et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 2002; 8:214-21.
5.
Yu V., Greenberg R., Zadeikis N., et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest. 2004; 125:2135-9.
6.
Dunbar L., Khashab M., Kahn J., Zadeikis N., Xiang J., Tennenberg A. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 2004; 20: 555-63.
7.
Антипин А.Н., Арсенин С.Л., Прилуцкая М.А., Белобородов В.Б.. Особенности диагностики и лечения внебольничной пневмонии, вызванной Legionella pneumophila. Российские медицинские вести 2004; (2):23-31.
8.
West M., Boulanger B., Fogarty C., et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003; 25:485-506.
9.
Bundrick W., Heron S., Ray P., et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology 2003; 62:537-41.
10.
Croom K., Goa L. Levofloxacin. A review of its use in the treatment of bacterial infections in the United States. Drugs 2003; 63:2769-802.
11.
Nightingale C., Grant E., Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy 2000; 46 (Suppl 1):6-14.
12.
Ball P. Efficacy and safety of Levofloxacin in the context of other contemporary fluoroquinolones: a review. Curr Ther Res 2003; 64:646-61.
13.
Kahn J. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy 2001; 47 Suppl 3):32-7.